ArticleOncotarget2019
Dysregulation of the TOX-RUNX3 pathway in cutaneous T-cell lymphoma.
Article in Oncotarget, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 34 citations in OpenAlex.
- scRNA-Seq reveals anti-lymphoma immune responses in mogamulizumab-associated skin eruptions.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Cutaneous T cell lymphoma atlas reveals malignant TNature immunology · 2024Article
- RUNX2 as a novel biomarker for early identification of patients progressing to advanced-stage mycosis fungoides.Frontiers in oncology · 2024Article
- Article
- The Tox Gene Encodes Two Proteins with Distinct and Shared Roles in Gene Regulation.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- TOX regulates T lymphocytes differentiation and its function in tumor.Frontiers in immunology · 2023Review
- TOX Expression in Mycosis Fungoides and Sezary Syndrome.Diagnostics (Basel, Switzerland) · 2022Article
- The pivotal role of cytotoxic NK cells in mediating the therapeutic effect of anti-CD47 therapy in mycosis fungoides.Cancer immunology, immunotherapy : CII · 2022Article
- Clinical Response to Anti-CD47 Immunotherapy Is Associated with Rapid Reduction of Exhausted Bystander CD4Cancers · 2021Article
- Review
- TOX as a potential target for immunotherapy in lymphocytic malignancies.Biomarker research · 2021Review
- Higher TOX Genes Expression Is Associated With Poor Overall Survival for Patients With Acute Myeloid Leukemia.Frontiers in oncology · 2021Article
- Hypopigmented Mycosis Fungoides: Loss of Pigmentation Reflects Antitumor Immune Response in Young Patients.Cancers · 2020Review
- High-mobility group box (TOX) antibody a useful tool for the identification of B and T cell subpopulations.PloS one · 2020Article
- Molecular Insights Into Pathogenesis of Peripheral T Cell Lymphoma: a Review.Current hematologic malignancy reports · 2018Review
- The biomarker landscape in mycosis fungoides and Sézary syndrome.Experimental dermatology · 2017Review
- T-cell lymphomas, a challenging disease: types, treatments, and future.International journal of clinical oncology · 2017Review
- CD164 identifies CD4Archives of dermatological research · 2017Article
- TOX expression and role in CTCL.Journal of the European Academy of Dermatology and Venereology : JEADV · 2016Article
- An overview of cutaneous T cell lymphomas.F1000Research · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Studies have examined gene expression changes in Sézary syndrome (SS), but disease pathogenesis remains largely unknown, and diagnosis and treatment are difficult.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.